Therefore, the consistent beneficial effects of BPC 157 therapy exclude poorly controlled NO increase (and therefore the consequent chain of negative events) (see below, Section 3.2) and poorly controlled effects on the increase of NOS gene expression (NOS-1, NOS-2, and NOS-3 gene expression)
GSH augmentation deserves investigation as a beneficial therapeutic approach for not only PD but also numerous other CNS disorders for which GSH deficiency and GSH-related enzyme deficits have been documented (multiple sclerosis, 25,26 autism, 2729 Alzheimers disease, 30,31 schizophrenia, 32,33 and bipolar disease 34 )
Therefore, dihexa's ability to reverse scopolamine-dependent deficits in water maze performance was established
Laboratory studies demonstrate
PMID: 16583442